Solution Areas

Tailored solutions that meet the most daunting challenges facing biopharma

Ambit is an analytics and technology-enabled services company that allows biopharma to adapt to the challenges and opportunities in the rare and specialty disease markets.

Patient ID and Activation

Ambit’s modular approach can address barriers to locate, engage, activate, and/or diagnose rare disease patients for clinical trials and approved products.

Strategy

Ambit is a future-focused partner for biopharma with the deep expertise needed to tackle challenges in rare and specialty disease.

Digital

We develop strategies to maximize the digital opportunity in healthcare with bespoke research and analysis, strategic planning, tactical road-mapping, and performance analytics.

Analytics

Ambit’s Analytics team has rich experience with advanced analytics techniques including AI, machine learning, deep learning, network and cluster analysis and visualization. We are well-versed with leading biopharma secondary databases and their integration, and offer tailored solutions based on specific data needs.

Digital Transformation

We help biopharma companies conceptualize their digital transformation strategy, develop roadmaps, and implement them through a human-centered approach that enhances patient outcomes, customer satisfaction, and business impacts.

Solution Areas

Tailored solutions that meet the most daunting challenges facing biopharma

Ambit is an analytics and technology-enabled services company that allows biopharma to adapt to the challenges and opportuni ties in the rare disease and specialty markets.

Solution Areas

Patient Identification

Ambit’s modular approach can address barriers to locate, engage, activate, and / or diagnose rare disease patients for clinical trials and approved products.

A new look for Ambit

Our brand may be changing, but our focus remains the same. We are committed to developing novel solutions that enable our biopharma clients to adapt to the challenges and opportunities in the rare and specialty disease markets.